Don't miss our next Lung Cancer Living Room! Join us Tuesday, July 16 at 5:30 pm (PT) to discuss the best of ASCO 2019 with Dr. Jacob Sands of Dana-Farber Cancer Institute. Watch on Facebook Live, YouTube, or the Living Room Library. The GO2 Science and Research team just returned from the 2019 American Society of Clinical Oncology (ASCO) meeting. We connect you and your loved ones to the latest research and treatment options by keeping up with [...]
On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option for non-small cell lung cancer, this is the first approval of pembrolizumab for small cell lung cancer. This approval was based on two clinical trials, KEYNOTE-158 and KEYNOTE-028, which measured tumor [...]
On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.
On March 18, the U.S. Food and Drug Administration approved a combination of the immunotherapy atezolizumab (Tecentriq) along with standard chemotherapy (carboplatin and etoposide) for patients who are starting treatment for extensive stage small cell lung cancer. This is the first immunotherapy approved up front, as a first treatment, for small cell lung cancer (SCLC). The approval was based on the IMPower133 clinical trial which showed that more patients survived longer when taking the combination than standard chemotherapy. Click here [...]
By Curt Hammock As I approached Christmas in 2010, I reflected on just how good I had it. My business was growing, I was riding my motorcycle, playing golf and getting ready to celebrate my wife, Elaine’s, birthday that month. During that time, I had a constant nose bleed my doctor assured me was due to the blood thinners I was on for a past heart attack. Later that month, I found a lump on my neck. My doctor put [...]
The LCA Science and Research team just returned from the 2019 Targeted Therapies of Lung Cancer Meeting, and we have good news: treatment options continue to expand in the targeted therapies and immunotherapy space to treat all types of lung cancer. Here’s what we learned. All of the advancements presented emphasize the importance of molecular testing/biomarker testing so that the best treatments can be chosen for a patient’s unique cancer. There are currently approved targeted therapies for patients whose cancers [...]
Last year was an exciting year for lung cancer research with more U.S. Food and Drug Administration (FDA) approval decisions relevant to lung cancer than ever before. So, what can we expect for 2019? Another eventful year with researchers studying how to best give the approved drugs (i.e. what order and combinations) as well as expanding the options with more types of therapies. IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER First, there is the rapidly growing field of immunotherapy. We have [...]
The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. This is the first four drug combination treatment approved for lung cancer. Click here to learn more.
Small cell lung cancer (SCLC) makes up about 15% of lung cancer cases (the other 85% is non-small cell lung cancer) with around 30,000 Americans being diagnosed each year. 98% of SCLC cases are smoking-related (majority of those diagnosed being former smokers). With smoking rates decreasing in the past several decades, so have rates of SCLC. The current standard of care for patients diagnosed with SCLC is chemotherapy and radiation (surgery can be an option if diagnosed at an early [...]
Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous non-small cell lung cancer (NSCLC). The results of the randomized trial showed an increase in overall survival, progression-free survival and overall response rate. Click here to read the full press release.